Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor
Conditions
Interventions
Evolocumab
Ezetimibe
+1 more
Locations
42
United States
Research Site
Anaheim, California, United States
Research Site
Mission Viejo, California, United States
Research Site
Westlake Village, California, United States
Research Site
Atlanta, Georgia, United States
Research Site
Atlanta, Georgia, United States
Research Site
Savannah, Georgia, United States
Start Date
July 28, 2011
Primary Completion Date
May 8, 2012
Completion Date
May 8, 2012
Last Updated
November 7, 2022
NCT07473960
NCT06062394
NCT07230730
NCT07334834
NCT07223658
NCT07311941
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions